SARS-CoV-2 and Influenza viruses are among the most common and highly contagious respiratory viruses worldwide. These viruses present significant health risks, particularly for infants, children, and the elderly. Individuals in these groups are at an increased risk of developing severe respiratory complications, including respiratory failure. While SARS-CoV-2 is responsible for the ongoing COVID-19 pandemic, Influenza A and B viruses cause seasonal flu outbreaks each year. Both types of viruses spread rapidly through respiratory droplets, making early detection crucial in preventing further transmission and initiating timely treatment.

The SARS-CoV-2 & Influenza A/B Rapid Antigen Test is designed to detect the simultaneous presence of specific Nucleocapsid (N) proteins for SARS-CoV-2, Influenza A, or Influenza B. This is achieved using a colored immunochromatographic assay that is simple and highly effective. The test works on swab specimens collected from individuals suspected of having SARS-CoV-2 or Influenza A/B infection. The results are available within just 10-15 minutes, making it an ideal solution for rapid diagnosis in clinical settings. Early detection allows healthcare professionals to quickly begin treatment and initiate necessary precautions to prevent the spread of these contagious viruses.

If the test result is positive, treatment can begin immediately, which is critical for preventing complications and reducing the severity of symptoms, especially for vulnerable populations. Timely diagnosis is key to controlling the spread of these viruses and minimizing their impact on public health. In addition, the rapid results provided by this test allow healthcare systems to respond more efficiently and reduce the burden on resources, especially during flu season or pandemic outbreaks.

The SARS-CoV-2 & Influenza A/B Rapid Antigen Test offers a significant advantage during times when both COVID-19 and seasonal influenza are circulating. With the ability to detect both viruses at once, it simplifies diagnosis, improves treatment timelines, and supports the swift isolation of infected individuals. This test is particularly useful in large-scale screenings, clinical settings, and public health initiatives to ensure rapid identification and containment of viral infections.

Sample types: nasopharyngeal and oropharyngeal swabs

Sensitivity: 98.5 %

Specificity: 99%

LoD: 125-500 cp/mL

Q-Check SARS-CoV-2 & Flu A/B Rapid Antigen Test            25T/Box                       QCH-0008-25

                                                                                     Single Test/Box               QCH-0008-1